RRAD and cancer: However, owing to the nonspecific cytotoxicity (MI/TI) and efficacy (AH) against cancers, Lee, Yeom demonstrated that RRAD inhibition results from the hydrogen bonding between oxeladin and the Gln250 of RRAD, and the pi-pi stacking interactions of oxeladin with the Lys228 or Arg249 of RRAD [35].